NASH/MASH Deal Benchmarks 2026

Median Upfront

$654M

Range: $359M - $937M

Total Deal Value

$3.1B

Range: $2.0B - $4.2B

Royalty Rate

14.4% - 26.3%

Tiered up to 30.3%

Dev Milestones

$440M

Range: $298M - $584M

Model Your Deal

Market Analysis

The NASH/MASH therapeutic landscape was transformed by resmetirom's (Rezdiffra) FDA approval in March 2024 — the first approved therapy for metabolic dysfunction-associated steatohepatitis. This validated the category and unlocked a wave of licensing deals. Madrigal Pharmaceuticals' market cap exceeded $7B on approval, setting the commercial benchmark for the class.

Phase 2 MASH small molecule deals command median upfront payments of $654M, with total deal values of $3.1B. GLP-1-based MASH approaches (leveraging semaglutide's MASH data) push even higher at $4.7B total value, reflecting the dual obesity/MASH opportunity.

Key deal drivers include fibrosis improvement data (F2-F3 reversal), combination strategies with GLP-1 agonists, and the massive undiagnosed patient population (estimated 6-8M in the US alone). Efruxifermin (FGF21 agonist) was acquired by Novo Nordisk for $1.4B, while survodutide (GLP-1/glucagon dual agonist) is being developed by Boehringer Ingelheim in a $1.6B partnership with Zealand.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What are MASH deals worth after resmetirom approval?

Phase 2 MASH deals average $3.1B total value. The resmetirom approval validated the category, increasing deal premiums 20-30% compared to pre-approval benchmarks.

How do MASH deal terms compare to obesity deals?

MASH deals command slightly lower valuations than pure obesity plays due to smaller addressable populations, but assets with dual obesity/MASH potential (like GLP-1-based approaches at $4.7B total value) attract premium terms.

What endpoints matter most for MASH deal valuations?

Fibrosis improvement (F2-F3 reversal without worsening MASH) is the gold-standard endpoint. Resolution of MASH without worsening fibrosis is also valued. Combination data with GLP-1 agonists can significantly increase deal premiums.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Related Benchmarks

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.

Start Calculating

For Funds & Advisors

Need the full deal landscape?

The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.

Configure Brief — $2,500All-inclusive · White-label · Walkthrough included

Market Analysis

Full Benchmark Analysis

Customize these benchmarks for your asset

Frequently Asked Questions

Full Benchmark Analysis

Related Benchmarks

Metabolic & Obesity Overview

GLP-1 Obesity Deal Benchmarks

Small Molecule Deal Benchmarks

Ready to Calculate Your Deal Terms?

Need the full deal landscape?